We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

New Delhi, Jan 9 (PTI) Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Drug sales rep's suit claims Eli Lilly violated his civil rights when it fired him over religious-themed posts on a company messageboard. Plaintiff's religious postings came after a manager's post ...

In the new filing, Lilly says it wants to wade into the legal proceedings to “protect its interests and help bring this suit to a swift end.” The company’s lawyers further contend that OFA ...

In a surprising twist, the bumbling yet endearing Michael Scott of The Office may represent a dying breed in corporate America. As companies increasingly slash management roles, the era of hands ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. ‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could ...